In March 2025, BioVersys announced that the first patient has been dosed in a pulmonary TB Phase 2 clinical trial, evaluating the early bactericidal activity (EBA) and safety of alpibectir-ethionamide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback